This list is an analysis based on recent market events. It's not an investment recommendation.
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Show more...
FAQ
What is Regnum stock price today?▼
The current price of RGMP is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Regnum stock price performance more closely on the chart.
What is Regnum stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Regnum stocks are traded under the ticker RGMP.
Is Regnum stock price growing?▼
RGMP stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Regnum has showed a +0% increase.
What were Regnum earnings last quarter?▼
RGMP earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Regnum revenue for the last year?▼
Regnum revenue for the last year amounts to 0 USD.
What is Regnum net income for the last year?▼
RGMP net income for the last year is -269,830 USD.
How many employees does Regnum have?▼
As of September 08, 2026, the company has 1 employees.
In which sector is Regnum located?▼
Regnum operates in the Health & Wellness sector.
When did Regnum complete a stock split?▼
Regnum has not had any recent stock splits.
Where is Regnum headquartered?▼
Regnum is headquartered in New York City, United States.